Kodu・Aktsiate loetelu・Johnson and Johnson

Johnson and Johnson

Suletud

SektorTervishoid

254.99 0.25

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

250.42

Max

255.5

Põhinäitajad
By Trading Economics
Sissetulek	299M 5.5B
Müük	1.2B 25B
P/E Sektori keskmine	29.548 68.51
Aktsiakasum	2.9
Dividenditootlus	2.04
Kasumimarginaal	21.865
Töötajad	138,200
EBITDA	-1.1B 7.2B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+9.81% upside

Dividendid
By Acuity
Dividenditootlus Sektori keskmine	2.04% 2.29%
Järgmine tulemuste avaldamine	13. okt 2026
Järgmine dividendimakse kuupäev	8. sept 2026
Järgmine aktsia dividendi kuupäev (ex-date)	25. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-5.5B 613B
Eelmine avamishind	254.74
Eelmine sulgemishind	254.99

Uudiste sentiment

By Acuity

24%

76%

87 / 340 Pingereas Healthcare

Johnson and Johnson Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

3. aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

1. aug 2026, 00:01 UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

31. juuli 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

30. juuli 2026, 18:22 UTC

News

Event

Johnson & Johnson shares are lower amid concerns over a $1 billion acquisition of Firefly Bio and a partnership with Sail Biomedicines, impacting future earnings.

29. juuli 2026, 21:41 UTC

News

Johnson & Johnson lowered its fiscal year 2026 adjusted EPS guidance to $10.86 to $11.01, contributing to a decline in after-market trading.

28. juuli 2026, 23:31 UTC

Johnson & Johnson shares are higher in after-market trading, remaining above their 20-day moving average after six consecutive daily gains.

27. juuli 2026, 23:31 UTC

News

Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

24. juuli 2026, 23:26 UTC

Johnson & Johnson shares declined in after-market trading, continuing a downward trend since Friday's close, despite the broader market's stability amid bond market concerns.

23. juuli 2026, 10:06 UTC

Event

Johnson & Johnson's OTTAVA™ Robotic Surgical System received FDA authorization. Shares are lower in pre-market trading amid broader market declines.

22. juuli 2026, 23:36 UTC

Event

Johnson & Johnson shares are higher in after-market trading following FDA authorization of the OTTAVA™ Robotic Surgical System, the first table-integrated soft tissue robotic system.

21. juuli 2026, 23:11 UTC

Shares of Johnson & Johnson are higher in after-market trading, with no specific news identified. The stock remains below its 20-day moving average.

20. juuli 2026, 19:26 UTC

Social Media

News

Johnson & Johnson shares are lower today, continuing a decline since Friday. The company targets $101 billion in revenue amid bearish technical trends.

Võrdlus sarnastega

Hinnamuutus

Johnson and Johnson Prognoos

Hinnasiht

By TipRanks

9.81% tõus

12 kuu keskmine prognoos

Keskmine 279.94 USD 9.81%

Kõrge 305 USD

Madal 255 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Johnson and Johnson 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

Osta

Hoia

Müü

Põhineb 17 analüütiku instrumendi Johnson and Johnson aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

87 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.